title: [Angioprotectors in the treatment of rosacea].
abstract: Rosacea - a common chronic inflammatory dermatosis (3-10% of all dermatoses) primarily affecting the skin of face. Numerous methods for the treatment of rosacea are defined by the diversity of etiologic and pathogenic factors of dermatosis, its stage and clinical form. But a significant role in its development, most researchers relate to vascular disturbances. It is suggested that vascular changes in this disease are the product of two interrelated pathological processes: the disturbances in integrity and tone of the vascular wall and disorganization of perivascular connective tissue. The results of these processes are formation of a stable dilatation of skin blood vessels clinically manifested by erythema and telangiectasia. Based on foregoing, The aim of this study was evaluation of therapeutic efficacy of Rutin Forte in complex treatment and prevention of rosacea. 30 patients with an erythematous stage of rosacea were under observation (20 women and 10 men) aged 25 to 50 years. The first group (15 patients) was treated by the standard procedure (Antibiotics, systemic metronidazole, antihistamines, traditional external therapy). Patients of the second group (15 people) additionally received a Rutin Forte containing long-acting vitamin C, zinc and selenium. The drug was administered at a dose of 2 capsule per day. Duration of treatment - 2 to 3 months. Observation period after treatment were 12 months. During this period we revealed a significant reduction of erythema, recurrence of disease in the second group of patients was not observed, but in the group of comparison recurrences were detected on 3rd month of follow up and the degree of erythema reduction was significantly less. Thus, the study revealed that Rutin Forte is an effective means for the treatment and prevention of the torpid relapsing forms of rosacea on erythematous stage of dermatosis.
authors.affiliation: Tbilisi State Medical University, Department of Dermatovenerology. Georgia.
authors.forename: N V
authors.initials: NV
authors.lastname: Tsiskarishvili
authors.affiliation: Tbilisi State Medical University, Department of Dermatovenerology. Georgia.
authors.forename: A
authors.initials: A
authors.lastname: Katsitadze
authors.affiliation: Tbilisi State Medical University, Department of Dermatovenerology. Georgia.
authors.forename: Ts
authors.initials: Ts
authors.lastname: Tsiskarishvili
authors.affiliation: Tbilisi State Medical University, Department of Dermatovenerology. Georgia.
authors.forename: L
authors.initials: L
authors.lastname: Tchitanava
authors.affiliation: Tbilisi State Medical University, Department of Dermatovenerology. Georgia.
authors.forename: N I
authors.initials: NI
authors.lastname: Tsiskarishvili
mesh_terms: D000287:Administration, Topical; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001205:Ascorbic Acid / Q000494:pharmacology / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000627:therapeutic use*; D004890:Erythema / Q000188:drug therapy; D005260:Female; D006633:Histamine Antagonists / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use; D008875:Middle Aged; D012393:Rosacea / Q000188:drug therapy* / Q000473:pathology; D012431:Rutin / Q000494:pharmacology; D012643:Selenium / Q000627:therapeutic use; D012867:Skin / Q000187:drug effects / Q000473:pathology; D016896:Treatment Outcome; D015032:Zinc / Q000627:therapeutic use
chemical_list: D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents; D003879:Dermatologic Agents; D006633:Histamine Antagonists; C000597449:Rutin Forte; D008795:Metronidazole; D012431:Rutin; D012643:Selenium; D015032:Zinc; D001205:Ascorbic Acid